VIVUS Inc (VVUS.O)
24 Jun 2016
BRIEF-Vivus receives notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets
* Received notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,132||--|
|Eisai Co., Ltd (4523.T)||¥5,409||--|
|Novo Nordisk A/S (NOVOb.CO)||kr.345.10||-3.10|
|Pfizer Inc. (PFE.N)||$33.97||-0.62|
|Merck & Co., Inc. (MRK.N)||$55.88||-1.80|
|Roche Holding Ltd. (ROG.S)||CHF241.00||-5.50|
|Roche Holding Ltd. (RO.S)||CHF246.20||-3.30|
|GlaxoSmithKline plc (GSK.L)||1,482.00p||+53.00|
|Eli Lilly and Co (LLY.N)||$74.33||+0.39|
|Arena Pharmaceuticals, Inc. (ARNA.OQ)||$1.81||-0.10|
Earnings vs. Estimates
Analyst Research Reports
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
Trading Report for (VVUS). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : Pechala's Reports
VIVUS Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.